Study Comparing Inhaled Amikacin Versus Placebo to Prevent Ventilator Associated Pneumonia
Status:
Recruiting
Trial end date:
2022-04-01
Target enrollment:
Participant gender:
Summary
The objective of the study is to prove that after the third day of invasive mechanical
ventilation a three-day course of inhaled amikacin reduces the incidence of subsequent VAP.
Parallel two group double blind randomized controlled clinical trial. Individual
randomization, performed on day 4 of invasive mechanical ventilation, will be stratified on
centre in order to account for variations in VAP prevention bundle implementation and use of
systemic antibiotics the day of randomization. Patients will be treated three consecutive
days with inhaled amikacin or placebo. Patients will be followed up daily in the intensive
care unit for the occurrence of VAP according to international guidelines until day 28.